• Price (USD)126.25
  • Today's Change3.27 / 2.66%
  • Shares traded1.02m
  • 1 Year change+51.76%
  • Beta1.0760
Data delayed at least 15 minutes, as of Dec 02 2022 21:00 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It is developing therapeutic candidates for a range of diseases and disorders, including Duchenne muscular dystrophy (Duchenne), Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) disorders. It commercializes three products, such as EXONDYS 51 (eteplirsen) Injection, VYONDYS 53 (golodirsen) Injection and AMONDYS 45 (casimersen) Injection. These commercial products are indicated for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51, exon 53 and exon 45 skipping. Its pipeline includes more than 40 programs at various stages of discovery, pre-clinical and clinical development.

  • Revenue in USD (TTM)876.05m
  • Net income in USD-716.23m
  • Incorporated2013
  • Employees840.00
  • Location
    Sarepta Therapeutics Inc215 1st St Ste 415CAMBRIDGE 02142-1213United StatesUSA
  • Phone+1 (617) 274-4000
  • Fax+1 (302) 636-5454
  • Websitehttps://www.sarepta.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Exact Sciences Corp2.01bn-716.37m8.17bn6.42k--2.62--4.08-4.10-4.1011.4517.540.30945.219.14312,320.30-11.05-13.65-12.11-15.0972.7574.77-35.73-39.582.20-19.040.4194--18.4977.8327.68--67.16--
Legend Biotech Corp116.94m-346.40m8.33bn1.07k--17.50--71.25-2.34-2.340.79562.840.1413--4.64109,184.90-41.84---53.94-------296.23--3.81--0.2276--18.65---27.26------
Novocure Ltd542.62m-81.69m8.56bn1.17k--19.21--15.77-0.7821-0.78215.204.240.47294.685.97464,973.40-7.12-7.62-8.05-8.8978.6875.32-15.05-12.027.62-14.220.559--8.2345.20-783.35--6.47--
Catalent Inc4.83bn421.00m9.40bn19.00k22.342.0011.501.952.342.3426.8126.110.47334.623.92253,947.404.184.594.645.2132.6232.748.839.402.064.050.47220.0020.7618.39-4.9135.5836.40--
Jazz Pharmaceuticals PLC3.58bn-18.69m9.86bn3.20k--3.5915.332.75-0.3149-0.314957.2043.650.31350.54596.521,119,994.00-0.05733.94-0.06154.2485.7991.47-0.182810.962.271.870.6760.0030.9115.77-238.16---24.32--
Repligen Corporation801.30m166.34m10.45bn1.85k65.055.6948.8313.042.892.8913.8933.050.34071.696.69432,664.707.073.998.444.5257.9256.8520.7614.921.73199.030.1341--83.0845.02114.0861.4975.14--
Sarepta Therapeutics Inc876.05m-716.23m10.80bn840.00--25.05--12.32-8.21-8.2110.064.910.30110.5534.991,042,913.00-24.62-22.01-29.58-25.2083.9187.56-81.76-101.073.99-11.050.7817--29.96164.5124.43--41.17--
Charles River Laboratories Intl. Inc3.78bn436.39m11.51bn18.60k26.644.3815.623.048.498.4973.6051.630.523710.705.28203,293.906.146.617.177.8537.3137.1511.7210.931.1418.980.52380.0021.0816.067.3220.4132.85--
Neurocrine Biosciences, Inc.1.39bn58.20m12.14bn900.00217.547.86167.728.740.58060.580614.3516.070.66750.62725.971,543,000.002.806.803.378.1998.5998.944.1911.522.41--0.0987--8.38137.50-78.00--41.62--
United Therapeutics Corporation1.86bn707.40m12.56bn965.0018.752.7516.576.7514.7014.7038.67100.130.34351.368.371,927,461.0013.0610.5813.8811.7393.1591.8138.0324.629.3918.570.14920.0013.631.06-7.58-7.7922.83--
BIO-TECHNE Corp1.12bn291.88m13.56bn3.00k48.427.7435.0612.141.781.786.8311.160.48372.646.95372,511.7012.298.4713.089.0368.4667.2325.4019.872.92--0.131329.5218.7514.4593.7929.0124.230.00
Viatris Inc16.73bn803.60m13.63bn37.00k17.040.71063.670.81480.65970.659713.7715.820.31952.555.02452,116.201.53-0.36851.82-0.442843.1938.974.80-
Data as of Dec 02 2022. Currency figures normalised to Sarepta Therapeutics Inc's reporting currency: US Dollar USD

Institutional shareholders

40.31%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Sep 20227.97m9.10%
Janus Henderson Investors US LLCas of 30 Sep 20226.46m7.38%
BlackRock Fund Advisorsas of 30 Sep 20223.81m4.35%
Avoro Capital Advisor LLCas of 30 Sep 20223.18m3.63%
Ecor1 Capital LLCas of 30 Sep 20223.00m3.43%
Wellington Management Co. LLPas of 30 Sep 20222.56m2.92%
Sands Capital Management LLCas of 30 Sep 20222.48m2.84%
Fidelity Management & Research Co. LLCas of 30 Sep 20222.41m2.75%
SSgA Funds Management, Inc.as of 30 Sep 20221.93m2.21%
Camber Capital Management LPas of 30 Sep 20221.50m1.71%
More ▼
Data from 30 Sep 2022 - 30 Sep 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.